Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large increase in short interest in the month of May. As of May 29th, there was short interest totaling 31,099 shares, an increase of 360.2% from the May 14th total of 6,757 shares. Based on an average daily volume of 125,406 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.0% of the shares of the company are sold short.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.47% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Bluejay Diagnostics Price Performance

Shares of Bluejay Diagnostics stock traded up $0.01 during trading on Thursday, hitting $4.50. 27,953 shares of the company’s stock traded hands, compared to its average volume of 854,678. The firm’s fifty day moving average price is $2.30 and its 200 day moving average price is $2.76. Bluejay Diagnostics has a twelve month low of $1.62 and a twelve month high of $16.68. The company has a market cap of $4.64 million, a PE ratio of -0.39 and a beta of 0.82.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Thursday, May 7th. The company reported ($1.95) earnings per share for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.